HC Wainwright Forecasts Strong Price Appreciation for Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S (NASDAQ:GMAB) had its target price raised by investment analysts at HC Wainwright from $40.00 to $41.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 43.06% from the company’s previous close.

Several other brokerages also recently commented on GMAB. Truist Financial reaffirmed a “buy” rating and set a $48.00 target price (down from $49.00) on shares of Genmab A/S in a report on Thursday. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price objective on the stock in a research note on Tuesday, September 23rd. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus price target of $39.75.

Genmab A/S Price Performance

Genmab A/S stock opened at $28.66 on Monday. The business has a 50 day moving average of $29.61 and a 200-day moving average of $24.49. The company has a market capitalization of $18.40 billion, a P/E ratio of 12.20, a P/E/G ratio of 1.56 and a beta of 0.96. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $33.65.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 24.48%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $975.40 million. Genmab A/S has set its FY 2025 guidance at EPS. Equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Orbis Allan Gray Ltd increased its stake in Genmab A/S by 38.7% in the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after purchasing an additional 2,209,659 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Genmab A/S by 152.3% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock valued at $71,367,000 after buying an additional 2,084,966 shares during the period. First Trust Advisors LP increased its position in Genmab A/S by 3.5% in the 2nd quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock valued at $36,575,000 after buying an additional 60,504 shares in the last quarter. Brandywine Global Investment Management LLC raised its stake in Genmab A/S by 1.6% during the 2nd quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock worth $36,047,000 after buying an additional 27,372 shares during the period. Finally, Cubist Systematic Strategies LLC raised its stake in Genmab A/S by 112.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 1,258,143 shares of the company’s stock worth $24,634,000 after buying an additional 665,893 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.